Johnson & Johnson to Host Enterprise Business Review
Key Highlights
- ➤Johnson & Johnson (JNJ) will host an Enterprise Business Review on December 8, 2026
- ➤Leaders will review Innovative Medicine and MedTech businesses, pipelines, and long-term strategy
- ➤Live General Session begins at 8:30 a.m. ET; event concludes around 3:45 p.m. ET
- ➤Presentations and demonstrations will showcase pipeline focus areas and healthcare innovation
Expert Statements
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson
“Enterprise overview”
Joe Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson
“financial overview”
Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, of Johnson & Johnson
“Perspectives on MedTech’s long-term commercial strategy and leadership in the highest-growth markets, positioning the business to lead the next era in medical technology”
Tom Cavanaugh, Executive Vice President, Worldwide Chairman, Innovative Medicine, of Johnson & Johnson
“Insights into Innovative Medicine’s industry-leading portfolio and transformational innovation fueling both short- and long-term growth”
John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine R&D, of Johnson & Johnson
“Insights into Innovative Medicine’s industry-leading portfolio and transformational innovation fueling both short- and long-term growth”
Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8(th), 2026. During the event, Company leaders will provide a detailed review of the Innovative Medicine and MedTech businesses, highlight how their pipelines are shaping the future of healthcare, and discuss the Company’s long-term strategy for delivering the next wave of growth and shareholder value.
The Enterprise Business Review will include a live General Session starting at 8:30 a.m. ET, followed by in-depth focus rotations, with the event concluding at approximately 3:45 p.m. ET. The program will feature:
Get started
Create a free account to read the full story.